Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tetracaine
Drug ID BADD_D02176
Description Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Indications and Usage Ophthalmic tetracaine is indicated for the for procedures requiring a rapid and short- acting topical ophthalmic anesthetic. The combination lidocaine and tetracaine patch is indicated for local dermal analgesia for superficial dermatological procedures and superficial venous access. The combination lidocaine and tetracaine cream is intended to provide topical local analgesia for superficial dermatological procedures.
Marketing Status approved; vet_approved
ATC Code C05AD02; D04AB06; N01BA03; S01HA03
DrugBank ID DB09085
KEGG ID D00551
MeSH ID D013748
PubChem ID 5411
TTD Drug ID D08HQK
NDC Product Code 51552-0323; 37945-212; 67194-020; 0395-8188; 52038-001; 70372-729; 54723-011; 51927-0007; 63275-9894; 66219-0003; 10695-087; 10695-187; 17381-099; 49452-7675; 82481-004; 62991-1708; 70859-009; 38779-0374
UNII 0619F35CGV
Synonyms Tetracaine | Tetrakain | Amethocaine | Dicaine | Pontocaine | Tetrracaine Hydrochloride | Hydrochloride, Tetrracaine | Tetracaine Monohydrochloride | Ametop | Pantocaine
Chemical Information
Molecular Formula C15H24N2O2
CAS Registry Number 94-24-6
SMILES CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Arachnoiditis17.06.01.001; 12.02.04.002--
Cardiac arrest02.03.04.001--
Chills15.05.03.016; 08.01.09.001--
Corneal oedema06.04.02.001--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Iritis06.04.03.002; 10.02.01.022--Not Available
Keratitis06.04.02.002--
Loss of consciousness17.02.04.004--Not Available
Meningism17.02.05.007--
Nausea07.01.07.001--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Nervousness19.06.02.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Pain08.01.08.004--
Paralysis17.01.04.004--Not Available
Seizure17.12.03.001--
Somnolence19.02.05.003; 17.02.04.006--
Tension19.06.02.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Conjunctival hyperaemia06.04.01.004--Not Available
Vasodilation procedure25.03.01.001--Not Available
Post lumbar puncture syndrome12.02.04.004; 17.14.01.012--Not Available
The 1th Page    1    Total 1 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene